THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, August 24, 2020
Sophia Genetics’ new AI tool can sift through data and work out how the COBVID-19 pandemic will evolve in the coming days.
FREMONT, CA: Switzerland-based medical data specialist Sophia Genetics rolls out a platform that will sift through data generated at more than 1,000 hospitals around the world to work out how the COVID-19 will evolve in the coming months. The data mining tool will be used to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 c transforms over time, along with patient genetic information gathered from lung and CT scans, and other clinical data.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
At the core of the system is an AI system to conduct a full-genome analysis of SARS-CoV-2 and a radiomics tool for lung data. Coupled, they use machine learning to identify abnormalities predictive of disease evolution.
Check Out This : Eldercare Review
There are many things about the virus and its associated clinical manifestations that is still not revealed. Also, elderly people are unfortunately at a much higher risk of suffering from severe forms of the disease, and experts do not understand why some healthy, young people can also go through a severe form of the disease while others remain completely asymptomatic. It is also unknown whether the virus sequence will evolve significantly through mutations as millions of more people become infected. Working out how COVID-19 manifests differently in different patient groups is a major roadblock that, if solved, could support in resource allocation for healthcare systems, including who should get early and aggressive treatment.
The latest tool can be used by labs in their own COVID-19 research projects on their local patient base, and in turn, could be leveraged by pharma that is developing candidate vaccines and antiviral therapies. This could potentially impact the efficacy and safety of candidate vaccines and antiviral therapies. Being able to conduct a longitudinal tracking of the viral genomic evolution across geographies and time is very significant.
The new tool could also be used to predict potential changes in efficacy down the line, for instance, if a mutation appears in the virus that would be in the target area of an antiviral drug. Controlling this virus means understanding it at several levels that go beyond mere testing. The evolution of COVID-19 must be predicted to create containment measures.
More in News